Skip to content

Comparison of Desflurane Anesthesia Versus TIVA-TCI in Patients Undergoing Ophthalmic Ambulatory Surgery

Comparison of Desflurane Balanced Anesthesia Versus TIVA-TCI (Total IntraVenous Anesthesia-Target Controlled Infusion) in Patients Undergoing Ophthalmic Ambulatory Surgery: A Single Center, Prospective, Randomized, Controlled Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02922660
Enrollment
209
Registered
2016-10-04
Start date
2016-10-31
Completion date
2018-01-31
Last updated
2018-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, Ophthalmic, Surgery

Keywords

Ambulatory surgery, Ophthalmic, Inhalation anesthesia, Desflurane, Total intravenous anesthesia

Brief summary

This is a single-center, randomized, prospective research which aims to investigate the advantages and disadvantages between desflurane balanced anesthesia and TIVA-TCI with propofol in ophthalmic ambulatory surgery, so that to evaluate a better anesthesia method in ophthalmic surgery through a large sample clinical study.

Detailed description

Desflurane balanced anesthesia and TIVA-TCI(Total IntraVenous Anesthesia-Target Controlled Infusion) are commonly used in ophthalmic ambulatory surgery, however, there is no clear evidence to discriminate the advantages and disadvantages between them. This study is designed to evaluate a better anesthetic method in ophthalmic surgery through a clinical study. This is a single center, randomized, prospective study. 200 patients with American Society of Anesthesiologists'(ASA) physical status 1 to 2, aged 18 to 60, scheduled for elective strabismus ambulatory and in whom a LMA is indicated for anesthesia are recruited. Enrolled patients are randomly assigned into 2 groups: group TIVA (TIVA-TCI with propofol) and group Des (Desflurane).In group TIVA, anesthesia is maintained with propofol and remifentanil. Propofol is continuously administered via a target-controlled infusion (TCI) pump intraoperatively. In group Des, anesthesia is maintained with desflurane.All patients received anaesthesia depth monitoring with bispectral index (BIS). The dose of anesthetic is adjusted to maintained the BIS value within 40 to 60. At the end of the surgery, inhalant anesthetic or infused propofol and remifentanil are discontinued. LMA is removed when patient regains consciousness with spontaneous respiration. Patients are then transferred to the post anesthetic care unit (PACU) for postoperative follow-up. The primary outcome is awake time, the secondary outcomes include discharge time, the stay time in PACU, time of off-bed, Riker sedation agitation score (SAS), time of PADSS\>9, NRS score when leaving PACU, incidence of various complications (postoperative nausea and vomiting (PONV), emergence agitation, etc), as well as anesthesia cost. All patients are followed up by calling in one day after the surgery.

Interventions

DRUGdesflurane

method of anesthesia maintenance with desflurane ranged from 0.5\ 1.5 MAC during the procedure

PROCEDUREtotal intravenous anesthesia

method of anesthesia in group TIVA is total intravenous anesthesia(TIVA) during the procedure

PROCEDUREinhalation anesthesia

method of anesthesia in group DES is inhalation anesthesia with desflurane during the procedure

DRUGPropofol

using propofol as sedative during the procedure of anesthesia and maintaining with propofol Cp 2-4 μg/ml in TCI

DRUGRemifentanil

using remifentanil as analgesics during the procedure of anesthesia and maintaining with remifentanil 2-4 ng/ml in TCI

Sponsors

Xiaoliang Gan
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* 18-60 years patients undergoing selective ophthalmic ambulatory surgery; * ASA I and II * duration of anesthesia at least 30min * without apparent organ comorbidities * sign the informed consent form

Exclusion criteria

* equal or greater than ASA III * has a history of dementia,psychiatric disorders or central nervous system diseases * taking sedatives, antidepressant or glucocorticoid * without family members * has cardiac, respiratory,liver,kidney comorbidities * uncontrolled hypertension(\>180/100mmHg) * laryngeal mask fail to insert, and change to tracheal intubation

Design outcomes

Primary

MeasureTime frameDescription
Awake timeFrom the ending time of anesthesia until the recovery time of patient's consciousness, assessed up to half an hour postoperatively.Anesthesia ends means stop infusing or inhaling any anaesthetic.

Secondary

MeasureTime frameDescription
Stay time in the postoperative care unitMeasuring the stay time in postoperative care unit, assessed up to one hour postoperatively.
Quality of recovery in 1 day postoperativelyStart scaling when 1 day(24 hour) postoperatively.It will use telephone follow-up for the patients enrolled.
Incidences in postoperative nausea and vomiting(PONV)Start scaling in 1 day(24 hour) postoperatively.
Discharge timeFrom the ending time of anesthesia until the time of extubation, assessed up to half an hour postoperatively.The standards of extubation are tidal volume(VT) 6~8 ml/kg,respiratory rate(RR) 10~12 times per minute,end-tidal carbon dioxide (ETCO2) 35~45 mmHg.
Anesthesia costDuring the procedure of anesthesia.
Postoperative VAS pain scoreStart scaling in half an hour postoperatively when patient's consciousness returns.
Incidences in postoperative agitationStart scaling in 1 day(24 hour) postoperatively.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026